Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Yunzhen Qian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-5220-5283; OpenAlex author ID A5091639391. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2020: 6 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 12

  1. Adipogenic transdifferentiation reprograms EMT-high PDAC cells into a post-mitotic adipocyte-like state and limits metastasis. Co-author DOI 10.1038/s41419-026-08613-4↗
  2. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12876-023-02748-w↗
  3. Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41389-022-00411-9↗
  4. Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2022/7353572↗
  5. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Co-author DOI 10.1016/j.bbcan.2020.188409↗
  6. High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12957-021-02147-z↗
  7. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.02.016↗
  8. HNF-1a promotes pancreatic cancer growth and apoptosis resistance via its target gene PKLR. Co-author DOI 10.1093/abbs/gmz169↗
  9. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Co-author DOI 10.1177/1073274820915947↗
  10. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-020-00958-3↗
  11. Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08301-3↗
  12. Lewis antigen‑negative pancreatic cancer: An aggressive subgroup. Co-author DOI 10.3892/ijo.2020.4989↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 11 shared papers, 2020–2023 · strength 1.32
  2. Chen Liu · 11 shared papers, 2020–2023 · strength 1.32
  3. Yitao Gong · 10 shared papers, 2020–2022 · strength 1.14
  4. Guopei Luo · 10 shared papers, 2020–2022 · strength 1.14
  5. He Cheng · 9 shared papers, 2020–2023 · strength 1.11
  6. Kaizhou Jin · 8 shared papers, 2020–2021 · strength 0.87
  7. Zhiyao Fan · 7 shared papers, 2020–2021 · strength 0.75
  8. Quanxing Ni · 6 shared papers, 2020–2021 · strength 0.67
  9. Yusheng Chen · 3 shared papers, 2022–2023 · strength 0.44
  10. Xu Wang · 3 shared papers, 2022–2023 · strength 0.44
  11. Xuan Lin · 3 shared papers, 2022–2023 · strength 0.44
  12. Xuan Zou · 3 shared papers, 2022–2023 · strength 0.44
  13. Yu Liu · 2 shared papers, 2021–2023 · strength 0.30
  14. Aziguli Tulamaiti · 1 shared paper, 2026 · strength 0.29
  15. Xueli Zhang · 1 shared paper, 2026 · strength 0.29
  16. Zhigang Zhang · 1 shared paper, 2026 · strength 0.29
  17. Dongxue Li · 1 shared paper, 2026 · strength 0.29
  18. Qi An · 1 shared paper, 2026 · strength 0.29
  19. Yesiboli Tasiheng · 2 shared papers, 2022 · strength 0.27
  20. Zhengjie Dai · 2 shared papers, 2022 · strength 0.27
  21. Chao Yang · 2 shared papers, 2020 · strength 0.20
  22. Weiding Wu · 1 shared paper, 2021 · strength 0.12
  23. Xu He · 1 shared paper, 2020 · strength 0.10
  24. Kun Fan · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.